Channel - Cancer Grand Rounds
10/28/2025 3:41:13 PM
Channel Videos
Advances in CAR-T Therapy in Lymphoma - N.Grover - 20260302
Chimeric antigen receptor T‑cell (CAR‑T) therapy has rapidly evolved from a treatment for relapsed/refractory large B‑cell lymphoma to an expanding platform with new targets, earlier‑line indications, and novel manufacturing approaches. This clinically focused Grand Rounds will review the most recent developments in CAR‑T therapy for lymphoma, including updates on efficacy, toxicity management, and emerging real-world data. The session will also highlight ongoing research in CD30-directedCAR‑T therapy and discuss its potential role across CD30‑expressing lymphomas. A patient who recently underwent CAR‑T treatment will share their journey to provide a firsthand perspective on decision-making, expectations, and survivorship.
Natalie Grover MD
2/3/2026 8:45:00 PM
Clinical Advances in Harnessing Therapy-Induced Immunity with ADCs and Cancer Vaccines - Z.Hartman - 20251118
Zachary Hartman PhD
11/18/2025 8:00:00 PM
Immunotherapy for Head and Neck Cancer: Opportunities and Dangers - R. Ferris -20260303
Immunotherapy has become integrated into therapy for many solid tumors. As this new modality has evolved through recurrent/metastatic and recently into the locally advanced setting, new insights and dangers have been encountered, providing insights into complex interactions of conventional modalities with immunotherapeutic modulation of the tumor microenvironment and clinical benefit for patients. The roles of treatment intensification and de-intensification using immunotherapy will be discussed.
Robert Ferris
3/3/2026 8:45:00 PM
Incorporating Menin Inhibitors into Frontline Therapy for Older Adults with AML: Light at the End of the Tunnel? - J.Zeidner - 20251104
Joshua Zeidner MD
11/4/2025 8:45:00 PM
Liquid Biopsies for the Detection and Molecular Characterization of Lung Cancer - M.Diehn - 20260120
Circulating nucleic acids represent promising biomarkers for non-invasive, sensitive, specific, and dynamic detection and characterization of cancers. While research in the field initially mainly focused on detection of tumor-derived mutations in patients with metastatic disease, more recent work has begun to explore applications in early-stage cancer patients and led to the development of methods for non-invasive analysis of gene expression. In this presentation, I will describe work our group has done to develop and apply novel assays for detection and analysis of circulating nucleic acids, including cell free DNA and RNA.
Maximilian Diehn, MD, PhD, FASCO
1/20/2026 8:45:00 PM
Locoregional Recurrence in ER+ HER2– Breast Cancer: Clinical Reality, Therapeutic Uncertainty, and the Need for Biologic Insight - M.Flanagan - 20260317
Locoregional recurrence (LRR) in breast cancer remains a clinically significant event associated with increased risk of distant metastasis and breast cancer–specific mortality. While advances in surgery, radiation, and systemic therapy have reduced recurrence rates, management of LRR—particularly in estrogen receptor–positive (ER+), HER2-negative disease—remains highly variable and is often guided by clinical judgment rather than tumor biology. This talk will review current patterns of locoregional recurrence, associated outcomes, and contemporary treatment approaches, highlighting areas of uncertainty in systemic therapy decision-making. The session will also introduce ongoing research aimed at understanding the molecular evolution of ER+ HER2– tumors at the time of recurrence, with the goal of informing more biologically driven treatment strategies during what may represent the final potentially curative opportunity.
Meghan Flanagan, MD, MPH, Associate Professor
3/17/2026 7:45:00 PM
Melanoma: A Case-Based Tour - F.Colichio - 20260106
Through a case-based presentation, we will tour the standard of care for patients with melanoma from stage IIB through stage 4 and we will explore some of the research avenues for patients who had had recurrence of their cancer after immune check point inhibitors.
Frances Collichio MD
1/6/2026 8:45:00 PM
Oligometastatic Cancers through the Lens of Genitourinary Cancers - C.Tang - 20251021
Chad Tang, MD, will discuss the evidence supporting the current application of radiation for oligometastatic cancers, specifically focusing on genitourinary cancers.
Chad Tang MD
10/21/2025 8:00:00 PM
Re-Evaluating Radioresistance in Soft Tissue Sarcoma - T.Yanagihara - 20260505
Ted K. Yanagihara, MD, PhD, will review the long-standing dogma that sarcoma represents a radioresistant histology and challenge this notion through a more nuanced, biology-driven lens. By distinguishing intrinsic radiosensitivity from observed clinical radioresponsiveness, we will explore how factors such as dose, fractionation, tumor microenvironment, and histologic subtype shape outcomes. We will also discuss emerging clinical trial data that are reshaping sarcoma management—including the growing integration of systemic therapies—and highlight ongoing clinical trials at our institution.
Ted Yanagihara MD, PhD
5/5/2026 7:45:00 PM
The Age of Oncogeriatrics - A.Rosko - 20260217
Ashley Rosko, MD, is a Professor of Hematology and first named Medical Director of the Oncogeriatric Program at the James Comprehensive Cancer Center at The Ohio State University. She will discuss the importance and relevance of introducing age-friendly assessments as part of routine oncology care and the incorporation of aging biomarkers in physiologic health assessment among cancer populations.
Ashley Rosko, MD
2/17/2026 8:45:00 PM
The Emerging Field of Adolescent and Young Adult Oncology Through the Lens of Germ Cell Tumors - L.Frazier - 20260519
An overview of the most common cancer in adolescent and young adults, germ cell tumors, and a discussion of how to build an AYA Center that is both patient and disease-centered.
Lindsay Frazier, MD, ScM
5/19/2026 7:45:00 PM
Where the Rubber Hits the Road: Genomic Biomarkers in Breast Cancer Clinical Decision-Making - L.Carey - 20251202
Lisa Carey, MD, FASCO, ScM, offers a clinically grounded tour of how genomic and immune biomarkers are transforming breast cancer care, from early-stage treatment decisions to metastatic disease management. Dr. Lisa Carey reviews the dramatic improvements in survival driven by targeted therapies, the biology underlying intrinsic tumor and immune subtypes, and the strengths and limitations of major biomarker assays in ER-positive, HER2-positive, and triple-negative breast cancers. Using evidence from large genomic datasets and key trials—including CALGB 40601, CALGB 40603, HER2DX development, and ongoing studies such as HARMONY—she illustrates how tumor subtype, immune activation, and molecular heterogeneity influence response to therapy, recurrence risk, and treatment tailoring. The session highlights where biomarkers work well, where they fall short, and what’s coming next, providing clinicians with a practical framework for matching the right patient to the right treatment at the right time.
Lisa Carey MD
12/2/2025 8:45:00 PM
Mediasite Showcase
Mediasite's the trusted cornerstone of any campus or enterprise video strategy. Our unyielding commitment to all things video helps you transform education, training, communications and online events.
Webcasting Video Content Management Video Delivery Integration Services Mediasite Community
Powered By Mediasite - Enterprise Video Platform